Register / Log In

AACR: Genetic Profiling May Optimize Cancer Treatment

Refractory cases in ovarian, colorectal, and breast cancer may benefit from genetic profiling


MONDAY, April 20 (HealthDay News) -- Testing for genetic variations may allow clinicians to adjust cancer treatments that optimize progression-free survival, according to several studies presented at the 100th Annual Meeting of the American Association for Cancer Research held from April 18 to 22 in Denver.

In one study, Daniel Von Hoff, M.D., from TGen, a non-profit research institute in Phoenix, and colleagues conducted molecular profiling of 66 patients with either refractory ovarian, colorectal, breast, or miscellaneous cancer. After the results suggested a new treatment, improvements in progression-free survival were significantly higher in patients with ovarian, breast, colorectal, and miscellaneous cancer (20 percent, 36 percent, 44 percent, and 16 percent, respectively).

In one of the other studies, researchers suggested that BRAF, PIK3CA and KRAS mutations and loss of PTEN expression impair response to epidermal growth factor receptor-targeted therapies in metastatic colorectal cancer.

"With this trial, we are showing the power of personalized medicine using the tools we already have available to us. As these tools become more precise and more effective, the value of personalized medicine will increase," Von Hoff said in a statement.

Abstract-Von Hoff
Abstract-Berndt
Abstract-Poole
Abstract-Pasche
Abstract-Slager
More Information

Copyright © 2009 ScoutNews, LLC. All rights reserved.